Valuation Highnoon Laboratories Limited

Stocks

End-of-day quote Pakistan S.E. 17/08/2026			5-day change	1st Jan Change
994.49 ^PKR	-0.90%		-1.47%	-2.74%

05-19	Highnoon Laboratories Appoints Dr. Shahzad Khan as Managing Director of Highnoon Life Sciences	CI
04-30	Highnoon Laboratories Limited Approves Final Cash Dividend for the Year Ended December 31, 2025	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	48,650	54,175	52,691	-	-
Change	-	11.36%	-2.74%	-	-
Enterprise Value (EV)	48,650	54,175	52,691	52,691	52,691
Change	-	11.36%	-2.74%	0%	0%
P/E	14.4x	-	-	-	-
PBR	-	-	-	-	-
PEG	-	-	-	-	-
Capitalization / Revenue	-	1.96x	1.73x	1.54x	1.37x
EV / Revenue	-	0x	1.73x	1.54x	1.37x
EV / EBITDA	-	-	-	-	-
EV / EBIT	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Dividend per Share ²	-	50	45	52	60
Rate of return	-	4.89%	4.52%	5.23%	6.03%
EPS ²	63.95	-	-	-	-
Distribution rate	-	-	-	-	-
Net sales ¹	-	27,706	30,398	34,163	38,399
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Net income	3,389	-	-	-	-
Net Debt	-	-	-	-	-
Reference price ²	918.22	1,022.49	994.49	994.49	994.49
Nbr of stocks (in thousands)	52,983	52,983	52,983	-	-
Announcement Date	26/03/25	07/04/26	-	-	-

¹PKR in Million²PKR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
HIGHNOON LABORATORIES LIMITED	-	-	-	4.48%	192M
ELI LILLY AND COMPANY	33.76x	12.18x	24.85x	0.59%	1,052B
JOHNSON & JOHNSON	28.96x	-	-	2.06%	627B
ABBVIE INC.	31.84x	7.42x	15.42x	2.75%	441B
ROCHE HOLDING AG	19.79x	4.7x	11.65x	2.81%	349B
NOVARTIS AG	21.42x	5.54x	13.77x	2.89%	287B
ASTRAZENECA PLC	19.89x	4.11x	11.68x	2.14%	241B
AMGEN INC.	26.26x	6.84x	12.14x	2.43%	224B
NOVO NORDISK A/S	13.32x	4.79x	9.96x	3.83%	202B
GILEAD SCIENCES, INC.	-42.28x	6.13x	23.96x	2.38%	172B
Average	17.00x	6.46x	15.43x	2.64%	359.54B
Weighted average by Cap.	24.17x	8.04x	17.73x	2%